Document Detail


5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression.
MedLine Citation:
PMID:  19590397     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Genes that regulate the serotonin signalling system are potential targets for research in the aetiology of mood disorders and also in the treatment response of serotonin reuptake inhibitors. In this study, we evaluated the association of seven serotonin signal transduction-linked single nucleotide polymorphisms [HTR1A (rs6295), HTR2A (rs6313, rs6311 and rs7997012), HTR6 (rs1805054), TPH1 (rs1800532) and TPH2 (rs1386494)] with major depressive disorder and/or treatment outcome with serotonin reuptake inhibitors. Patients who met the criteria for major depressive disorder were treated for 6 weeks with fluoxetine, paroxetine or citalopram. The treatment response was evaluated with the Montgomery-Asberg Depression Rating Scale, and according to predefined response criteria, the patients were divided into responders, nonresponders, remitters and nonremitters. Altogether, 86 patients completed the entire study according to the study protocol. We had also a control population (N = 395) of healthy blood donors. None of the seven single nucleotide polymorphisms was associated with major depressive disorder or with treatment response in our study population of Finnish individuals.
Authors:
Ari Illi; Eija Setälä-Soikkeli; Merja Viikki; Outi Poutanen; Heini Huhtala; Nina Mononen; Terho Lehtimäki; Esa Leinonen; Olli Kampman
Related Documents :
8378417 - The pharmacologic treatment of depression: drug selection criteria.
1882697 - Low brain uptake of l-[11c]5-hydroxytryptophan in major depression: a positron emission...
15892657 - The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, ph...
11500997 - The expert consensus guideline series. treatment of depression in women.
15621097 - The effects of dimethyl sulfoxide on liver damage caused by ischemia-reperfusion.
3944837 - Metabolic rate alterations in early excision and grafting versus conservative treatment.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neuroreport     Volume:  20     ISSN:  1473-558X     ISO Abbreviation:  Neuroreport     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-07-10     Completed Date:  2009-09-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100935     Medline TA:  Neuroreport     Country:  England    
Other Details:
Languages:  eng     Pagination:  1125-8     Citation Subset:  IM    
Affiliation:
University of Tampere, Medical School, Tampere, Finland. ari.illi@uta.fi
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Citalopram / therapeutic use
Depressive Disorder, Major / drug therapy*,  genetics*
Fluoxetine / therapeutic use
Humans
Middle Aged
Paroxetine / therapeutic use
Polymorphism, Single Nucleotide*
Psychiatric Status Rating Scales
Receptor, Serotonin, 5-HT1A / genetics
Receptor, Serotonin, 5-HT2A / genetics
Receptors, Serotonin / genetics
Serotonin Uptake Inhibitors / therapeutic use*
Treatment Outcome
Tryptophan Hydroxylase / genetics
Young Adult
Chemical
Reg. No./Substance:
0/Receptor, Serotonin, 5-HT2A; 0/Receptors, Serotonin; 0/Serotonin Uptake Inhibitors; 0/serotonin 6 receptor; 112692-38-3/Receptor, Serotonin, 5-HT1A; 54910-89-3/Fluoxetine; 59729-33-8/Citalopram; 61869-08-7/Paroxetine; EC 1.14.16.4/TPH1 protein, human; EC 1.14.16.4/TPH2 protein, human; EC 1.14.16.4/Tryptophan Hydroxylase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neural process underlying gap detection for spectrally rich and asymmetrical markers.
Next Document:  Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacety...